PRAMIPEXOL MYLAN PHARMACEUTICALS 0,18 mg COMPRIMIDOS EFG España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

pramipexol mylan pharmaceuticals 0,18 mg comprimidos efg

mylan pharmaceuticals, s.l. - pramipexol dihidrocloruro monohidrato - comprimido - 0,18 mg - pramipexol dihidrocloruro monohidrato 0,18 mg - pramipexol

PRAMIPEXOL MYLAN PHARMACEUTICALS 0,7 mg COMPRIMIDOS EFG España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

pramipexol mylan pharmaceuticals 0,7 mg comprimidos efg

mylan pharmaceuticals, s.l. - pramipexol dihidrocloruro monohidrato - comprimido - 0,7 mg - pramipexol dihidrocloruro monohidrato 0,7 mg - pramipexol

CLOPIDOGREL PHARMACIA 75 mg COMPRIMIDOS RECUBIERTOS CON PELICULA EFG España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

clopidogrel pharmacia 75 mg comprimidos recubiertos con pelicula efg

pharmacia grupo pfizer, s.l. - clopidogrel - comprimido recubierto con pelÍcula - 75 mg - clopidogrel 75 mg - clopidogrel

ROPINIROL PHARMACIA 1 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

ropinirol pharmacia 1 mg comprimidos recubiertos con pelicula efg

pharmacia grupo pfizer, s.l. - ropinirol hidrocloruro - excipientes: lactosa monohidrato,croscarmelosa sodica,croscarmelosa sodica - agentes dopaminÉrgicos - agonistas dopaminérgicos - ropinirol

Budesonide/Formoterol Teva Pharma B.V. Unión Europea - español - EMA (European Medicines Agency)

budesonide/formoterol teva pharma b.v.

teva pharma b.v. - budesonide, formoterol - asma - medicamentos para la enfermedad obstructiva de las vías respiratorias enfermedades, - budesonida / formoterol teva pharma b. está indicado únicamente en adultos de 18 años de edad o mayores. asthmabudesonide/formoterol teva pharma b. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: orin patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists. in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.

Pregabalin Mylan Pharma Unión Europea - español - EMA (European Medicines Agency)

pregabalin mylan pharma

mylan s.a.s. - pregabalina - anxiety disorders; neuralgia; epilepsy - los antiepilépticos, - epilepsypregabalin mylan pharma está indicado como terapia adyuvante en pacientes adultos con crisis parciales con o sin generalización secundaria. de ansiedad generalizada disorderpregabalin mylan pharma está indicado para el tratamiento del trastorno de ansiedad generalizada (tag) en adultos.

Clopidogrel Taw Pharma (previously Clopidogrel Mylan) Unión Europea - español - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - clorhidrato de clopidogrel - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - agentes antitrombóticos - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

LINEZOLID KERN PHARMA 600 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

linezolid kern pharma 600 mg comprimidos recubiertos con pelicula efg

kern pharma s.l. - linezolid - comprimido recubierto con pelÍcula - 600 mg - linezolid 600 mg - linezolid

CLOPIDOGREL MYLAN PHARMACEUTICALS 75 mg COMPRIMIDOS RECUBIERTOS CON PELICULA EFG España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

clopidogrel mylan pharmaceuticals 75 mg comprimidos recubiertos con pelicula efg

mylan pharmaceuticals, s.l. - clopidogrel - comprimido recubierto con pelÍcula - 75 mg - clopidogrel 75 mg - clopidogrel